{"id":9879,"date":"2026-05-21T10:15:34","date_gmt":"2026-05-21T10:15:34","guid":{"rendered":"https:\/\/evolutioneurope.eu\/?post_type=success-stories&#038;p=9879"},"modified":"2026-05-21T10:15:34","modified_gmt":"2026-05-21T10:15:34","slug":"raydiax-eic-accelerator-oncologia-intervencionista","status":"publish","type":"success-stories","link":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/","title":{"rendered":"RAYDIAX GmbH \u2013 RAYDIAX TACT"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":9886,"template":"","meta":{"_acf_changed":false},"flags":[93],"program":[46],"sector":[36],"class_list":["post-9879","success-stories","type-success-stories","status-publish","has-post-thumbnail","hentry","flags-de","program-instrumento-pyme-eic-accelerator","sector-salud"],"acf":{"layouts_cases":[{"acf_fc_layout":"content","content":{"sections_settings":{"section_id":"","section_background":false,"section_padding":"base"},"content":"<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">El Problema<\/h4>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">La Oncolog\u00eda Intervencionista se est\u00e1 consolidando como el cuarto pilar del tratamiento del c\u00e1ncer, ofreciendo ventajas claras frente a la cirug\u00eda tradicional: menos complicaciones, procedimientos m\u00e1s breves y estancias hospitalarias m\u00e1s cortas. Sin embargo, los sistemas de imagen que se utilizan hoy fueron concebidos originalmente para diagn\u00f3stico, no para guiar intervenciones oncol\u00f3gicas complejas en tiempo real.<\/p>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Esto se traduce en limitaciones en la precisi\u00f3n para localizar el tumor, en una mayor exposici\u00f3n a la radiaci\u00f3n, en una menor eficiencia del flujo de trabajo y en la dificultad para gestionar las complicaciones. Actualmente no existe en el mercado ning\u00fan sistema de imagen dise\u00f1ado espec\u00edficamente para responder a las exigencias de la oncolog\u00eda intervencionista moderna.<\/p>\r\n\r\n<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">El Proyecto<\/h4>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong><a class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/www.raydiax.com\/\" target=\"_blank\" rel=\"noopener\">Raydiax<\/a> <\/strong>ha desarrollado<strong> TACT (Therapy Assistance Computed Tomograph)<\/strong>, el primer sistema de imagen pensado espec\u00edficamente para la oncolog\u00eda intervencionista.<\/p>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">TACT combina TC y angiograf\u00eda en un sistema h\u00edbrido compacto \u00ab2 en 1\u00bb e integra innovaciones propias de hardware y software. Su tecnolog\u00eda patentada \u00abspotlight\u00bb permite reducir hasta un 40 % la dosis de radiaci\u00f3n, mientras que el software dedicado al flujo de trabajo intervencionista y el seguimiento de la aguja basado en imagen mejoran de forma sustancial la precisi\u00f3n, la usabilidad y la seguridad.<\/p>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Al transformar la imagen m\u00e9dica de una herramienta diagn\u00f3stica en una plataforma terap\u00e9utica integrada, TACT hace posible realizar intervenciones oncol\u00f3gicas m\u00e1s precisas, eficientes y accesibles.<\/p>\r\n\r\n<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">El Impacto<\/h4>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Con el apoyo estrat\u00e9gico de Evolution Europe, Raydiax ha obtenido <strong>financiaci\u00f3n combinada del <a class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/evolutioneurope.eu\/es\/eic-accelerator\/\" target=\"_blank\" rel=\"noopener\">EIC Accelerator<\/a><\/strong> para completar la validaci\u00f3n cl\u00ednica, obtener las aprobaciones CE y de la FDA, y preparar la comercializaci\u00f3n del sistema.<\/p>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">TACT permite a los hospitales reducir los costes de las intervenciones, aumentar el n\u00famero de pacientes tratables y disminuir significativamente las necesidades de espacio. Al hacer accesible la oncolog\u00eda intervencionista avanzada m\u00e1s all\u00e1 de los centros altamente especializados, Raydiax contribuye a extender una atenci\u00f3n oncol\u00f3gica de alta calidad a una poblaci\u00f3n de pacientes mucho m\u00e1s amplia.<\/p>\r\n\r\n<h4 class=\"text-text-100 mt-2 -mb-1 text-base font-bold\">El Resultado<\/h4>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Como resultado de esta exitosa <strong>solicitud al EIC Accelerator<\/strong>, Raydiax ha asegurado una financiaci\u00f3n combinada para acelerar la aprobaci\u00f3n regulatoria, la validaci\u00f3n y la entrada al mercado de TACT, compuesta por una<strong> subvenci\u00f3n de 2,5 millones de euros y 6 millones de euros de inversi\u00f3n en capital<\/strong>, lo que supone un <strong>total aproximado de 8,5 millones<\/strong> <strong>de euros de financiaci\u00f3n<\/strong> europea p\u00fablico-privada.<\/p>\r\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Este hito posiciona a la compa\u00f1\u00eda para establecer un nuevo est\u00e1ndar global en imagen para la oncolog\u00eda intervencionista e impulsar la pr\u00f3xima generaci\u00f3n de tratamientos oncol\u00f3gicos de precisi\u00f3n.<\/p>"}}],"layouts":null},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.3 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RAYDIAX GmbH \u2013 RAYDIAX TACT - evolution-europe<\/title>\n<meta name=\"description\" content=\"Raydiax obtiene 8,5 M\u20ac del EIC Accelerator para TACT, el primer sistema h\u00edbrido TC-angiograf\u00eda para oncolog\u00eda intervencionista.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RAYDIAX GmbH \u2013 RAYDIAX TACT\" \/>\n<meta property=\"og:description\" content=\"Raydiax obtiene 8,5 M\u20ac del EIC Accelerator para TACT, el primer sistema h\u00edbrido TC-angiograf\u00eda para oncolog\u00eda intervencionista.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/\" \/>\n<meta property=\"og:site_name\" content=\"evolution-europe\" \/>\n<meta property=\"og:image\" content=\"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/05\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/\",\"name\":\"RAYDIAX GmbH \u2013 RAYDIAX TACT - evolution-europe\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg\",\"datePublished\":\"2026-05-21T10:15:34+00:00\",\"description\":\"Raydiax obtiene 8,5 M\u20ac del EIC Accelerator para TACT, el primer sistema h\u00edbrido TC-angiograf\u00eda para oncolog\u00eda intervencionista.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/#primaryimage\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"CT of joints in a clinic with blue color and red scanning laser. computer diagnostics of injuries, inflammatory and dystrophic joint diseases for girl.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/raydiax-eic-accelerator-oncologia-intervencionista\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Success stories\",\"item\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/casos-de-\u00e9xito\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"RAYDIAX GmbH \u2013 RAYDIAX TACT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"name\":\"evolution-europe\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#organization\",\"name\":\"Evolution Europe\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"contentUrl\":\"https:\\\/\\\/evolutioneurope.eu\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/social-share-image-2000x1600-1.jpg\",\"width\":2000,\"height\":1600,\"caption\":\"Evolution Europe\"},\"image\":{\"@id\":\"https:\\\/\\\/evolutioneurope.eu\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RAYDIAX GmbH \u2013 RAYDIAX TACT - evolution-europe","description":"Raydiax obtiene 8,5 M\u20ac del EIC Accelerator para TACT, el primer sistema h\u00edbrido TC-angiograf\u00eda para oncolog\u00eda intervencionista.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/","og_locale":"es_ES","og_type":"article","og_title":"RAYDIAX GmbH \u2013 RAYDIAX TACT","og_description":"Raydiax obtiene 8,5 M\u20ac del EIC Accelerator para TACT, el primer sistema h\u00edbrido TC-angiograf\u00eda para oncolog\u00eda intervencionista.","og_url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/","og_site_name":"evolution-europe","og_image":[{"width":2560,"height":1707,"url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/05\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/","url":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/","name":"RAYDIAX GmbH \u2013 RAYDIAX TACT - evolution-europe","isPartOf":{"@id":"https:\/\/evolutioneurope.eu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/#primaryimage"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/#primaryimage"},"thumbnailUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/05\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg","datePublished":"2026-05-21T10:15:34+00:00","description":"Raydiax obtiene 8,5 M\u20ac del EIC Accelerator para TACT, el primer sistema h\u00edbrido TC-angiograf\u00eda para oncolog\u00eda intervencionista.","breadcrumb":{"@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/#primaryimage","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/05\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/05\/Raydiax-success-story-ct-scanner-clinic-with-blue-lighting-red-scanning-laser-scaled.jpg","width":2560,"height":1707,"caption":"CT of joints in a clinic with blue color and red scanning laser. computer diagnostics of injuries, inflammatory and dystrophic joint diseases for girl."},{"@type":"BreadcrumbList","@id":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/raydiax-eic-accelerator-oncologia-intervencionista\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/evolutioneurope.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Success stories","item":"https:\/\/evolutioneurope.eu\/es\/casos-de-\u00e9xito\/"},{"@type":"ListItem","position":3,"name":"RAYDIAX GmbH \u2013 RAYDIAX TACT"}]},{"@type":"WebSite","@id":"https:\/\/evolutioneurope.eu\/es\/#website","url":"https:\/\/evolutioneurope.eu\/es\/","name":"evolution-europe","description":"","publisher":{"@id":"https:\/\/evolutioneurope.eu\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/evolutioneurope.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/evolutioneurope.eu\/es\/#organization","name":"Evolution Europe","url":"https:\/\/evolutioneurope.eu\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/","url":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","contentUrl":"https:\/\/evolutioneurope.eu\/wp-content\/uploads\/2026\/04\/social-share-image-2000x1600-1.jpg","width":2000,"height":1600,"caption":"Evolution Europe"},"image":{"@id":"https:\/\/evolutioneurope.eu\/es\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories\/9879","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/success-stories"}],"about":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/types\/success-stories"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media\/9886"}],"wp:attachment":[{"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/media?parent=9879"}],"wp:term":[{"taxonomy":"flags","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/flags?post=9879"},{"taxonomy":"program","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/program?post=9879"},{"taxonomy":"sector","embeddable":true,"href":"https:\/\/evolutioneurope.eu\/es\/wp-json\/wp\/v2\/sector?post=9879"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}